Alzheimer’s Drugs Market Report 2021-2028 | Size, Share, Growth, Trends, Competitive Landscape, Revenue, Forecast Report

Pune, India, July 14, 2021 (GLOBE NEWSWIRE) -- Increasing prevalence of Alzheimer's disease is fueling the demand for Alzheimer’s drugs which in turn is driving the global Alzheimer’s drugs market, says Fortune Business Insights in a report, titled “Alzheimer’s Drugs Market”, Size, Share and Global Trend By Drug Class (Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Antagonist, Combination Drugs, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Geography Forecast till 2026.

Rising R&D activities by pharmaceutical companies and research institutes for Alzheimer effective therapy is expected to boost the global Alzheimer’s drugs market.

Request a Sample Copy of the Research Report:

The report covers:

  • Global Alzheimer’s Drugs Market trends, with detailed analysis on consumer trends & manufacturer trends.
  • Overview on supply analysis covering trends across raw material suppliers, technology providers and distributors.
  • Key areas of investments identifying market opportunities and challenges in forecast timeframe.
  • Competitive analysis of the industry players along with the overview on strategic management.
  • Comprehensive company profiles of the major industry players.

Increasing R&D Investments by Pharmaceutical Companies Will Propel Growth 

The active study of Alzheimer’s drug by pharmaceutical industries and research institutes for creating a strong pipeline for effective therapy is predicted to encourage growth of the global Alzheimer’s drugs market. According to the World Health Organization (WHO) currently, 50 million people are affected by dementia, and the number is expected to increase during the forecast period. In addition, the increasing cases of Alzheimer’s disease around the world have led towards high demand for Alzheimer’s drugs, which in turn is boosting the global Alzheimer’s drugs growth.

The Collaboration Between Eli Lilly and AC Immune Will Aid Growth 

Eli Lilly and Company and AC Immune SA announced their partnership agreement to research and develop tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease (AD) and other neurodegenerative diseases. The collaboration between the two companies is predicted to benefit Alzheimer’s drugs revenue owing to the Morphomer™ platform technology which will offer commercial capabilities in central nervous system disorders along with AC Immune's lead molecule, ACI-3024. Furthermore, the development of digital tools for Alzheimer’s disease and dementia is also expected to contribute to the global Alzheimer’s drugs growth. For instance, the Alzheimer's Drug Discovery Foundation (ADDF), announced a new initiative -Diagnostics Accelerator program that aims to track the development of digital tools for Alzheimer’s disease and dementia.

For more information in the analysis of this report, visit:

Leading Players operating in the Alzheimer’s Drugs Market are:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

  • Hoffmann-La Roche Ltd,
  • Novartis AG,
  • Pfizer Inc.,
  • Eli Lilly and Company.,
  • Merck Sharp & Dohme Corp.,
  • AstraZeneca,
  • Biogen,
  • AbbVie Inc.,
  • other players

Have Any Query? Ask Our Experts:

Increasing Prevalence of Alzheimer’s Disease Will Boost Growth in North America

Geographically, the global Alzheimer’s drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The global Alzheimer’s drugs market is predicted to expand in North America during the forecast period owing to the rising cases of Alzheimer’s disease and the presence of key players in the region. According to Alzheimer’s Association, currently, 5.8 million Americans are living with Alzheimer’s, and the number is expected to increase to 14 million by 2050, which is expected to promote the growth of the Alzheimer’s drugs market in North America.

Europe is predicted to grow significantly during the forecast period owing to the increasing prevalence of Alzheimer’s disease. Improving diagnostic capabilities are also expected to boost the market in the region. Evolving healthcare infrastructure and rising awareness regarding Alzheimer’s disease are expected to contribute significantly to Alzheimer’s drugs growth in Asia Pacific and Latin America. Additionally, Alzheimer’s drugs market in Middle East & Africa is in the nascent stage; however, unmet needs for Alzheimer’s disease is expected to drive the Alzheimer’s drugs market in this region.

Global Alzheimer’s Drugs Market Segmentation

By Drug Class 

  • Cholinesterase Inhibitors
  • N-Methyl-D-Aspartate (NMDA) Antagonist
  • Combination Drugs
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Application

  • North America (USA and Canada)
  • Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Get your Customized Research Report:


  • Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companies
  • Details in relation to prevalence, incidence, patient numbers, distribution of patients, average price of treatment, etc.
  • Number of end user facilities by region/country and average annual spending or procurement of devices by type of end user facility
  • Number of procedures and average price of procedures
  • Replacement rate and pricing of capital equipment
  • Market dynamics in relation to the market under focus – Drivers, restraints, trends, and opportunities
  • Market & technological trends, new product developments, product pipeline.

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Fortune Business Insights™
LinkedIn | Twitter | Blogs

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.